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Introduction
It has long been recognised that people diagnosed with melanoma face an increased risk of being diagnosed with a subsequent in situ or invasive melanoma. 1, 2 In addition to increased awareness and medical surveillance, one possible explanation is that these people may possess certain characteristics that predispose them to develop this disease. 3, 4 In situ melanoma is the earliest stage of the disease and occurs when a malignant melanocytic proliferation is confined to the epidermis. They are thought to be precursors of invasive melanoma, although this is yet to be proven. 1 Studies have found that survival following diagnosis of an in situ melanoma is equivalent to that of the general population, 1, 3 which is to be expected given the lack of potential for an in situ melanoma to metastasise.
While these findings seem to suggest that in situ melanomas do not have any prognostic implications, it is possible that they might modify the host immune system, 5 and hence carry the potential to impact the prognosis of a subsequent or preceding invasive tumour. We therefore examined whether survival for persons with a single primary invasive melanoma varied by the presence or timing of an additional in situ melanoma.
Methods and Results
The study cohort consisted of all patients diagnosed with a single primary invasive cutaneous The study cohort was stratified into the six categories shown in the column headings of Table   1 , depending on whether and when an in situ melanoma was diagnosed in relation to the invasive melanoma. These categories were arbitrarily selected in order to detect any possible differences in survival by the length of time between diagnosis of the invasive and in situ melanomas.
Mortality status was followed up until 31 December 2012. For persons who had not died prior, survival was censored either at that date or 10 years from the time of diagnosis of the invasive melanoma, whichever occurred first. Unadjusted cause-specific 10-year survival was calculated using the Kaplan-Meier method, with delayed entry where the in situ melanoma was diagnosed after the invasive melanoma. Corresponding adjusted hazard ratios and 95%
confidence intervals were obtained from multivariate flexible parametric survival models, 6 adjusted for sex as well as body site, clinicopathological subtype, thickness and ulceration of the invasive melanoma. The model providing the best fit was on the normal scale with two knot points, and including time-varying effects for body site, thickness group and ulceration.
A total of 25,493 individuals were included in the study cohort. Median age at diagnosis of the invasive melanoma varied from 56 years for those without an in situ melanoma to 70 years where the in situ melanoma was diagnosed between two to five years prior to the invasive melanoma (Table 1) . Persons with a subsequent in situ melanoma tended to have more favourable prognostic attributes for the invasive melanoma compared to those without an in situ melanoma or who had either a prior or synchronous in situ melanoma; for example, the former group contained a lower proportion of invasive lesions on the head and neck, less nodular melanomas and fewer tumours thicker than 2mm.
Unadjusted cause-specific 10-year survival ranged from 88% for those with a preceding in situ melanoma diagnosed two or more years prior to the invasive melanoma, to 94% if an in situ melanoma was diagnosed at least two years subsequently, with an intermediate result (90%) for cases with an invasive melanoma only ( Table 2 and Figure 1 ). However, no significant differences in 10-year cause-specific mortality were detected by the presence or timing of an in situ melanoma after multivariate adjustment (p=0.99 for the overall effect).
Conclusion
Several recent studies [7] [8] [9] have examined the effect of multiple melanomas on survival outcomes. These papers have reported conflicting results, mainly because they differ in their approach to defining multiple invasive melanomas, with some authors also including multiple in situ tumours. Our large population-based study demonstrates that an additional in situ melanoma does not have any prognostic influence on survival for an invasive melanoma, irrespective of whether the in situ melanoma was diagnosed prior, synchronously or subsequent to the invasive lesion. This is important because the unnecessary inclusion of in situ melanomas could act to dilute any potential differences in survival between patients with a single melanoma compared to those with multiple invasive melanomas.
A small increase in the unadjusted survival rates that was observed for invasive melanoma cases with a subsequent in situ melanoma compared to those with a prior in situ melanoma appears to be linked to age at diagnosis. The disparity in the age distribution may also help to explain the higher proportion of some of the other more favourable prognostic characteristics that were observed for individuals who had a subsequent in situ melanoma. For example, melanomas on the head and neck are associated with lower survival and are more common at an older age. 10 An advantage of the current study is that it utlised a large, population-based cohort consisting of high quality data (>98% histological verification). Data on key prognostic indicators were missing for some cases, particularly ulceration of the invasive melanoma (36% not stated);
however, this distribution did not vary significantly across the various study cohorts. The proportion of invasive melanomas with clinicopathological subtype classified as "not otherwise specified" differed from 21% to 31% depending on if and when an in situ melanoma was also diagnosed, and thereby may alter the percentage apportioned to the remaining subtypes. Data on mitoses, another key prognostic indicator for melanoma, was not available from the Queensland Cancer Registry.
In summary, our study found that in situ melanoma has no additional impact on survival beyond that of an invasive melanoma, and so would support the premise that future studies of survival for multiple melanoma need only include invasive lesions. However, previous research has shown that persons with an in situ melanoma have a significantly elevated risk of being subsequently diagnosed with an invasive melanoma. 2 Therefore, while the in situ melanoma itself does not impact survival, continued surveillance following diagnosis of an in situ melanoma should remain a priority. 
